Having trouble accessing articles? Reset your cache.

Sharpless’ priorities reflect continuity with Gottlieb

Acting FDA Commissioner Ned Sharpless laid out similar priorities to those of his predecessor in an all-hands email sent Tuesday to FDA employees, including a push to approve generics and biosimilars, develop modern guidance for emerging technologies, and

Read the full 382 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE